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Abstract 
Acute erythroid leukemia (FAB-M6) and acute megakaryoblastic leukemia 
(FAB-M7) exhibit closely related properties in cells regarding morphology 
and the gene expression profile. Although allogeneic hematopoietic stem cell 
transplantation (allo-HSCT) is considered the mainstay of the treatment for 
both subtypes of leukemia due to their refractoriness to chemotherapy and 
high rates of relapse, it remains unclear whether allo-HSCT is curative in 
such cases due to their scarcity. We retrospectively examined the impact of 
allo-HSCT in 382 patients with M6 and 108 patients with M7 using 
nationwide HSCT data and found the overall survival (OS) and relapse rates 
of the M6 patients to be significantly better than those of the M7 patients 
after adjusting for confounding factors and statistically comparable with 
those of the patients with M0/M1/M2/M4/M5 disease. Consequently, the 
factors of age, gender, performance status, karyotype, disease status at 
HSCT and development of graft-versus-host disease predicted the OS for the 
M6 patients, while the performance status and disease status at HSCT were 
predictive of the OS for the M7 patients. These findings substantiate the 
importance of distinguishing between M6 and M7 in the HSCT setting and 
 4 / 22 
 
suggest that unknown mechanisms influence the HSCT outcomes of these 
closely related subtypes of leukemia. 
 
Keywords: acute erythroid leukemia, acute megakaryoblastic leukemia, 
allogeneic hematopoietic stem cell transplantation. 
 




All blood cell lineages are derived from a common hematopoietic stem cell1. A 
current dendrogram describing the process of blood cell fate determination 
postulates megakaryocyte and erythroid series to arise from common 
megakaryocyte-erythroid progenitors2-6, and similarity between the 
erythroid and megakaryocytic lineages has been observed in terms of 
differentiation, regulation by growth factors and epigenetics7-10. In an 
analogous fashion, two rare subtypes of acute myeloid leukemia (AML), 
acute erythroid leukemia (M6 according to the FAB classification) and acute 
megakaryoblastic leukemia (M7 according to the FAB classification), are 
considered to be closely related in origin due to their morphologic similarity3 
as well as common patterns of the gene expression11. Both M6 and M7 are 
considered indications for allogeneic hematopoietic stem cell transplantation 
(allo-HSCT) in view of the poor prognosis of patients not treated with this 
procedure12-15. However, it remains uncertain whether the use of allo-HSCT 
for M6 or M7 of AML definitively improves the prognosis because the data 
are limited based on the fact that M6 and M7 comprise less than 5% of all 
AML cases. If M6 and M7 are innately identical, there may be similarities in 
 6 / 22 
 
 
allo-HSCT outcomes  between these two diseases. We therefore conducted 
a retrospective study to examine the outcomes of allo-HSCT in patients 




2.1 Study population 
The data for de novo AML patients 16 years of age or older who underwent 
initial allo-HSCT between January 1996 and December 2010 were obtained 
from the Transplant Registry Unified Management Program (TRUMP) in Japan16. The 
clinical features and outcomes of these patients were investigated. The 
subtypes of M6 according to the FAB classification, M6a and M6b, were not 
distinguished in the database. The diagnosis which was made according to 
the results of a FACS analysis and the data and the risk status based on the 
cytogenetic subgroup was categorized at each institution, instead of a central 
review, according to the Southwestern Oncology Group criteria for favorable 
and unfavorable risks17; all others were included in the intermediate-risk 
category18. In addition, clinical data were collected from the databases of the 
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Japan Society for Hematopoietic Cell Transplantation (JSHCT) and the 
Japan Cord Blood Bank Network using a standardized report form. This 
study was approved as an adult AML working group study by the Committee 
for Nationwide Survey Data Management of the JSHCT (study #2-12). 
2.2 Statistical analysis 
The characteristics of the M6 and M7 patients were compared using Fisher’s 
exact test for categorical variables and the t-test for continuous variables. 
Overall survival (OS) was defined as the number of days from HSCT until 
death from any cause. Relapse-free survival (RFS) was defined as the 
number of days from HSCT to relapse of the underlying disease. Non-relapse 
mortality (NRM) was defined as death without relapse. Any patient who 
remained alive on the last date of follow-up was censored. The OS rates were 
calculated using the Kaplan-Meier method and compared using the log-rank 
test. The cumulative incidences of NRM (CI-NRM) and relapse were 
calculated considering each other type of event as a competing risk and 
compared using the stratified Grey test. Multivariate Cox models were used 
to evaluate the hazard ratios associated with the prognosis. The following 
variables related to survival were compared in a univariate analysis: 
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recipient characteristics (age: younger than 50 years vs. older than 50 years, 
blood type, gender, performance status at diagnosis: 0 to 2 vs. 3 or 4, FAB 
classification: M6 vs. M7 and cytogenetic subgroup), donor characteristics 
(blood type, blood type compatibility, gender, gender compatibility, 
relationship: related vs. unrelated and serological HLA compatibility), 
transplant characteristics (days from diagnosis to HSCT: less than 90 days, 
90 days to 180 days, longer than 180 days, disease status at allo-HSCT: 
complete remission (CR) vs. non-CR, intensity of the preconditioning 
regimen (myeloablative vs. reduced intensity), use of total body irradiation 
as a preconditioning regimen, source of the graft: bone marrow (BM), 
peripheral blood stem cells (PBSCs) or cord blood (CB), the year of HSCT 
(before 2005 or after 2006) and transplant outcomes (development of acute 
graft-versus-host disease (GVHD): 0 or 1 vs. 2 to 4, development of chronic 
GVHD and relapse). The development of GVHD was treated as a 
time-dependent covariate. Covariates found to be significant in the 
univariate analyses (P ≤ 0.10) were included in the Cox’s proportional 
hazards models and Fine and Gray’s proportional hazards models. For both 
the univariate and multivariate analyses, P values were two-sided and 
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outcomes were considered to be significant for P ≤ 0.05. Matched-pair 
analysis was performed matching for the recipient’ age, cytogenetic subgroup, 
disease status at HSCT, conditioning regimen, donor selection and graft 
source. All statistical analyses were performed using the EZR program 
(Saitama Medical Center, Jichi Medical University)19, a graphical user 
interface for R (The R Foundation for Statistical Computing; 
http://www.r-project.org, version 2.14.1). 
 
3 Results 
3.1 Characteristics of the patients 
The number of AML patients with M6 and M7 was 382 and 108, respectively 
(Table 1). No favorable cytogenetic risk patients were included in this study.  
There were no significant difference in age, WBC, the proportion of patients 
with CR1 at allo-HSCT or the cytogenetic subgroup between the two groups; 
however, the proportion of patients with any CR at allo-HSCT was lower in 
the M7 group than in the M6 group (34% vs. 46%, p<0.04) and the degree of 
HLA disparity was more significant in the M7 group than in the M6 group 
(proportion of HLA match HSCT: 64% in M6 vs. 57% in M7, p<0.02). These 
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findings were consistent with the low remission rates in M7. 
3.2 Outcomes after allo-HSCT 
The OS and relapse-free survival (RFS) rates were significantly inferior in 
the M7 patients than in the M6 patients (Figure 1, 5-year OS of the M6 
patients and M7 patients: 35% and 17%, respectively (P<0.0003); 5-year RFS 
of the M6 patients and M7 patients: 34% and 14%, respectively (P<0.0002)). 
The CI-NRM was not significantly different between these two groups 
(Figure 2(a), 3-year CI-NRM: 22% in the M6 patients and 27% in the M7 
patients, P=0.29); however, the CI-relapse rate was significantly worse in the 
M7 patients than in the M6 patients (Figure 2(b), 3-year CI-relapse for the 
M6 patients and M7 patients: 30% and 46%, respectively (P<0.02)). The 
CI-relapse rates among the patients with CR at HSCT were significantly 
worse in the M7 group than in the M6 group, whereas those for the patients 
without CR at HSCT were comparable between these two groups (Figure 2(c) 
and 2(d), 3-year CI-relapse for the M6 patients with and without CR and the 
M7 patients with and without CR: 19% and 43% (P<0.004) and 42% and 48% 
(P=0.59), respectively). Therefore, we speculate that the primary factor of a 
worse OS in the M7 patients than in the M6 patients was caused by the 
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relatively higher rate of relapse in the M7 patients with CR. 
When the outcomes after allo-HSCT were compared between the M6 
and M7 patients and the M0-M5 (except M3) patients using a matched-pair 
analysis (Table 2), the M7 patients showed significantly worse OS, RFS and 
CI-relapse rates than the M0-M5 patients, while the M6 patients 
demonstrated comparable outcomes with the M0-M5 patients (Figure 3, 
5-year OS, 5-year RFS, 3-year CI-relapse and 3-year CI-NRM for the M7 
patients and paired M0-M5 patients: 12% and 34% (P<0.001), 17% and 33% 
(P<0.01), 47% and 33% (P<0.05) and 36% and 35%, respectively). The current 
results may therefore suggest that only M7 is a poor prognostic factor in 
HSCT for AML patients. 
3.3 Prognostic factors affecting the OS in the M6 patients and M7 
patients 
The univariate analysis of the M6 and M7 patients showed that age, gender, 
performance status at HSCT, FAB classification, cytogenetic subgroup, 
disease status at HSCT, graft source, HLA disparities, HSCT year and the 
development of GVHD were associated with the OS (Table 3). Furthermore, 
age, gender, performance status at HSCT, FAB classification, cytogenetic 
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subgroup, disease status at HSCT and the development of chronic GVHD 
remained significant factors in the multivariate analysis using Cox's 
proportional hazards model. The competing risks of relapse and non-relapse 
mortality were affected by age, performance status at HSCT, cytogenetic 
subgroup, disease status at HSCT, major ABO mismatch, graft source and 
the development of chronic GVHD for relapse mortality and HLA disparities 
for non-relapse mortality using a fine-gray analysis. When the patients with 
M6 and patients with M7 were analyzed separately, age, gender, 
performance status at HSCT, cytogenetic subgroup, disease status at HSCT 
and the development of GVHD where found to predict the OS rate in the M6 
patients, while the performance status and disease status at HSCT predicted 
the OS in the M7 patients (Table 4). 
 
4 Discussion 
Allo-HSCT is expected to provide curability for patients with AML by 
eliminating leukemic stem cells with allo-reactive donor T-cells20-23. We 
hypothesized that two infrequent subtypes of AML, M6 and M7, comprise 
leukemic stem cells with the same properties in the context of the 
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graft-versus-leukemia effect, thus showing similar transplant outcomes, 
since M6 and M7 are considered to originate from a common 
megakaryocyte-erythroid progenitor. The current study revealed that 
patients with M7 show inferior survival rates after allo-HSCT to those with 
M6, primarily due to the higher relapse rate observed in patients with M7. 
One plausible explanation for this difference in outcome is that the M7 
subtype is more prone to internal tandem duplications of FLT3 (FLT3-ITD), 
the most common mutations associated with an adverse disease outcome, 
than the M6 subtype24. Another possibility is that myelofibrotic changes may 
occur frequently in M7 patients15, and the post-transplant outcomes of 
patients with M7 associated with myelofibrosis, especially in severe cases, is 
dismal25, 26. In contrast, of the detection of myelofibrotic changes is rare in 
patients with M6 disease, as supported by the findings of a previous study27. 
Unfortunately, the present registry-based data did not include information 
regarding genetic abnormalities or fibrotic changes, and an examination of 
these parameters was outside of the scope of the present study. Therefore, 
further studies are warranted. 
It is well known that M7 is associated with Down syndrome. There were no 
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M7 cases complicated with Down syndrome; however, 1 patient had a sole 
trisomy 21 abnormality. One patient had trisomy 21 and trisomy 8, and 4 
patients had a complex cytogenetic abnormality containing trisomy 21 in our 
cohort. In contrast, 9 pediatric patients with M7 had sole trisomy 21 and 
received allo-HSCT. According to the current data, adult M7 patients with 
trisomy 21 did not receive allo-HSCT for some reason. 
The current findings demonstrated a poor prognosis among the M7 
patients after allo-HSCT. However, the outcome analysis showed a better 
performance status and CR at the time of allo-HSCT to be favorable 
prognostic factors. Although the transplantation of cord blood is superior to 
other graft sources in terms of competing risks of relapse, no superiority of 
cord blood with respect to overall survival was observed in the multivariate 
analysis. One possible reason for this finding is that the benefit of a lower 
risk of relapse induced by cord blood transplantation is offset by a higher 
risk of non-relapse mortality associated with HLA disparities resulting from 
cord blood transplantation. New treatment strategies are thus needed to 
improve the outcomes of M7 patients who do not achieve CR with remission 
induction therapy; unfortunately however, no promising reports have been 
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published regarding specific gene abnormalities for M7, and 
molecular-targeted therapy is not expected to achieve a significant 
improvement in treatment outcomes. As it stands, therefore, it is necessary 
to reconsider which treatment strategy will obtain the best outcome using 
currently available tools and techniques. 
 
5 Conclusions 
In the present study, the allo-SCT outcomes of the M7 patients were 
significantly inferior to those of the M6 patients, suggesting that M7 differs 
clinically from M6 as a disease entity. Employing a centralized database 
enables researchers to analyze rare disease entities, such as M6 and M7. 
Nevertheless, further prospective validation studies including genetic 
analyses are needed to verify the current results.  
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Figure legends 
Figure 1. Survival of the M6 and the M7 patients. 
(a) Rates of overall survival (OS). (b) Rates of relapse-free survival (RFS). 
Solid line, M6 patients; dashed line, M7 patients. 
 
Figure 2. Cumulative incidence (CI) of events after allo-HSCT. 
(a) CI of non-relapse mortality (NRM). 
(b)-(d) CI of relapse. (b) All patients; (c) patients in CR at HSCT; (d) patients 
in non-CR at HSCT.  
Solid line, M6 patients; dashed line, M7 patients. 
 
Figure 3. Survival and the CI of events after allo-HSCT of the M6 and the 
M7 patients compared with matched M0-M5 patients. 
(a) Rates of OS. (b) Rates of RFS. (c) CI of NRM. (d) CI of relapse.  
Solid line, M6 patients; dashed line, M7 patients; dotted line, M0-M5 
patients (except M3 patients). 
  
Table captions 
Table 1. Characteristics of patients. 
*: one patient transplanted BM+PBSC are not included. 
Abbreviations: BM; bone marrow, CB; cord blood, CR; complete remission, 
HSCT; hematopoietic stem cell transplantation, PBSC; peripheral blood 
stem cell. 
 
Table 2. Characteristics of patients in matched-pair analysis. 
*: one patient transplanted BM+PBSC are not included. 
Abbreviations: BM; bone marrow, CB; cord blood, CR; complete remission, 
HSCT; hematopoietic stem cell transplantation, PBSC; peripheral blood 
stem cell. 
 
Table 3. Prognostic factors affecting clinical outcomes. 
a. overall survival. 
Abbreviations: BM; bone marrow, CB; cord blood, CR; complete remission, 
GVHD; graft-versus-host disease, HSCT; hematopoietic stem cell 
transplantation, PBSC; peripheral blood stem cell. 
b. competing risk, relapse.  
Abbreviations: GVHD; graft-versus-host disease, HSCT; hematopoietic stem 
cell transplantation. 
c. competing risk, non-relapse death.  
 
Table 4. Prognostic factors affecting clinical outcomes, distinctively 
from M6 to M7 patients.  
a. M6 patients. 
b. M7 patients. 

















male/female 268 / 114 78 / 30 p=0.72







intermediate / poor 260 / 122 63 / 45 p=0.07
Performance status,
0-1 / 2-4 264 / 48 68 / 19 p=0.19
HSCT Year,
-2000 / 2001-2005 / 2006- 67 / 95 / 220 20 / 26 / 62 p=0.98
Diagnosis to HSCT,
<=90 / 90<SCT<=180 / 180< 45 / 144 /190 12 / 43 / 51 p=0.89
Disease status at HSCT,
CR/non-CR 175 / 207 37 / 71 p<0.04
Conditioning regimen,
Myeloablative / Reduced intensity 233 / 149 60 / 48 p=0.32
Donor selection,
Related / Unrelated 148 / 234 49 / 59 p=0.22
Graft source,
BM / PBSC / CB 220* / 67 / 94 70* / 20 / 17 p=0.16
HLA disparities,
0 / 1 / 2 / 3 223 / 50 / 73 / 4 56 / 24 / 14 / 4 p<0.02
*: one patient transplanted BM+PBSC are not included.
Abbreviations: BM; bone marrow, CB; cord blood, CR; complete remission, HSCT; hematopoietic
stem cell transplantation, PBSC; peripheral blood stem cell.



















male/female 268 / 114 226 / 156 p<0.002 78 / 30 42 / 66 p<0.0001
Cytogenetic subgroup,
intermediate / poor 260 / 122 260 / 122 p=1.00 63 / 45 64 / 44 p=1.00
Performance status,
0-1 / 2-4 264 / 48 263 / 49 p=1.00 68 / 19 70 / 11 p=0.23
HSCT Year,
-2000 / 2001-2005 / 2006- 67 / 95 / 220 67 / 106 / 209 p=0.66 20 / 26 / 62 28 / 21 / 59 p=0.22
Diagnosis to HSCT,
<=90 / 90<SCT<=180 / 180< 45 / 144 / 190 25 / 100 / 255 p<0.0001 12 / 43 / 51 56 / 92 / 12 p=0.38
Disease status at HSCT,




233 / 149 233 / 149 p=1.00 60 / 48 61 / 47 p=1.00
Donor selection,
Related / Unrelated 148 / 234 148 / 234 p=1.00 49 / 59 49 / 59 p=1.00
Graft source,
BM / PBSC / CB 220* / 67 / 94 221 / 67 / 94 p=1.00 70* / 20 / 17 71 / 20 / 17 p=1.00
*: one patient transplanted BM+PBSC are not included.
Abbreviations: BM; bone marrow, CB; cord blood, CR; complete remission, HSCT; hematopoietic stem cell
transplantation, PBSC; peripheral blood stem cell.
Table 3. Prognostic factors affecting clinical outcomes
a. overall survival b. competing risk, relapse
HR 95% CI P HR 95% CI P
16-49 1 16-49 1
≥50 <0.0001 1.39 1.07-1.81 <0.02 ≥50 1.45 1.01-2.08 <0.05
female 1 0, 1 1
male <0.0001 1.57 1.16-2.11 <0.004 ≥2 2.33 1.47-3.67 <0.0003
0, 1 1 intermediate 1
≥2 <0.0001 2.50 1.82-3.43 <0.0001 poor 2.46 1.65-3.65 <0.0001
M6 1 CR 1
M7 <0.0003 1.60 1.20-2.13 <0.002 non-CR 2.07 1.38-3.10 <0.0005
intermediate 1 no 1
poor <0.0001 2.09 1.59-2.74 <0.0001 yes 1.46 1.01-2.11 <0.05
CR 1 BM 1
non-CR <0.0001 1.93 1.43-2.59 <0.0001 PB 1.23 0.81-1.85 0.33
BM CB 0.46 0.26-0.81 <0.008
PBSC <0.02 no 1





0, 1 c. competing risk, non-relapse death
≥2 <0.006
chronic GVHD no 1 HR 95% CI P
yes <0.0003 0.36 0.25-0.50 <0.0001 0 1
1 2.12 1.17-3.85 <0.02
2 1.72 0.90-3.26 0.1
3 4.38 1.16-16.5 <0.03
NA
















Abbreviations: BM; bone marrow, CB; cord blood, CR; complete remission,
GVHD; graft-versus-host disease, HSCT; hematopoietic stem cell transplantation,



















Abbreviations: GVHD; graft-versus-host disease, HSCT;







HR 95% CI P
16-49 1
≥50 1.62 1.19-2.21 <0.003
female 1
male 1.79 1.25-2.58 <0.002
0, 1 1
≥2 2.06 1.40-3.03 <0.0003
intermediate 1
poor 2.48 1.79-3.44 <0.0001
CR 1
non-CR 1.84 1.31-2.57 <0.0001
0, 1 1
≥2 0.71 0.52-0.97 <0.04
no 1
yes 0.37 0.25-0.55 <0.0001
(b) M7 patients
HR 95% CI P
0, 1 1
≥2 3.17 1.80-5.60 <0.0001
CR 1
non-CR 3.55 1.87-6.75 <0.0002
Abbreviations: GVHD; graft-versus-host disease, HSCT;























Table 4. Prognostic factors affecting clinical outcomes, distinctively
from M6 to M7 patients.
Variables Risk factors
